Journal article
Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?
Leukemia & lymphoma, v 62(3), pp 538-548
23 Feb 2021
PMID: 33251899
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The role of consolidative radiotherapy (RT) is less substantiated in uncommon peripheral T-cell lymphomas (PTCLs). Anaplastic lymphoma kinase (ALK) mutation sub-categorizes PTCLs, with ALK (+) having a distinctly favorable prognosis. We aimed to use the National Cancer Database to examine the potential role of RT in PTCLs and if ALK mutation can be used to predict the benefit of consolidative RT after multi-agent chemotherapy (combined modality therapy). We identified 3670 stage I-II PTCL patients treated with multi-agent chemotherapy alone or combined modality therapy (CMT) between 1998-2012. After adjusting for immortal-time and indication bias, CMT was associated with better OS than multi-agent chemotherapy alone for ALK (−) patients (HR 0.69, 95% CI 0.52-0.92, p = .01); no significant difference was noted for ALK (+) (HR 1.03, 95% CI 0.75-1.41, p = .85). CMT is associated with improved OS for ALK (−) PTCLs; while no such benefit was seen for the ALK (+) subgroup.
Metrics
Details
- Title
- Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?
- Creators
- Joshua L. Rodríguez-López - University of Pittsburgh School of MedicineAnkur K. Patel - UPMC Hillman Cancer CenterGoundappa K. Balasubramani - University of PittsburghScott M. Glaser - City Of Hope National Medical CenterSushil Beriwal - UPMC Hillman Cancer CenterJohn A. Vargo - UPMC Hillman Cancer Center
- Publication Details
- Leukemia & lymphoma, v 62(3), pp 538-548
- Publisher
- Taylor & Francis
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000596966300001
- Scopus ID
- 2-s2.0-85096946386
- Other Identifier
- 991021897277304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Hematology
- Oncology